Curium to Acquire Lantheus in $8 Billion All-Cash Deal
Curium, supported by CapVest Partners, is set to acquire Lantheus, a prominent US radiopharmaceutical company, in a significant all-cash transaction valued at nearly $8 billion. This acquisition will transition Lantheus, currently listed on Nasdaq, into a private entity. Under the terms of the agreement, Curium US will purchase all outstanding shares of Lantheus at a price of $102.50 per share upon closing. Additionally, Lantheus shareholders will receive non-transferable contingent value rights (CVRs) that could yield up to an extra $12.00 per share if specific commercial milestones are achieved by 2030, bringing the total potential consideration per share to $114.50.
The offer represents a notable 38% premium over Lantheus’ 60-day volume-weighted average price and a 29% premium over its 30-day average. It is also 21% above the company's closing price on May 21, 2026, the last trading day before reports of the potential sale surfaced. The proposed transaction has garnered unanimous approval from Lantheus’ Board of Directors.
For Your Trading Desk
Sponsor Spike Success.
Mary Anne Heino, executive chair and CEO of Lantheus, expressed that this transaction validates the company’s achievements over seven decades in radiopharmaceutical innovation. She emphasized that the merger with Curium combines two pioneering companies with complementary strengths, aiming to enhance patient access to vital diagnostics and therapeutics.
Curium CEO Renaud Dehareng highlighted that Lantheus is an ideal partner to accelerate Curium's growth strategy. He noted that the merger would integrate Curium’s theranostics capabilities with Lantheus’ US radiodiagnostics business, enhancing their offerings in oncology, neurology, and cardiology across more than 70 countries. Dehareng stated that the combination would provide a broader range of theragnostic options, from SPECT and PET diagnostics to targeted radioligand therapies, ultimately reaching more patients and clinicians globally.
The acquisition will be financed through a combination of debt and equity, with no financial conditions attached. The companies anticipate that the merger will close in the first half of 2027, subject to regulatory approvals and the consent of Lantheus’ shareholders. Until the transaction is finalized, Lantheus will continue to operate as an independent, publicly listed company.




